BioPharmSignal logoBioPharmSignal

Biotech News

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

Clearside Biomedical (CLSD)Clearside Biomedical2026-06-25 13:46 ESTClinical readout

- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet

Open original release

Related news

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

CLSDClearside Biomedical2026-06-25 13:46 EST

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Clearside Biomedical

Clearside Biomedical is a medical devices company focused on product adoption, procedure volume, and how clinical workflow converts into recurring demand.

Recent company news

CLSDClearside Biomedical2026-06-26 14:05 EST

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

CLSDClearside Biomedical2026-06-26 14:05 EST

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

CLSDClearside Biomedical2026-06-26 14:05 EST

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

CLSDClearside Biomedical2026-06-26 14:05 EST

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

CLSDClearside Biomedical2026-06-26 14:05 EST

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States